Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Wynn Resorts, Limited — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $358.46 (market cap $9.43B), while Wynn Resorts, Limited trades at $103.57 (market cap $10.79B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock and Wynn Resorts, Limited are close in size by market cap, and Wynn Resorts, Limited pays a 0.95% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | WYNN | |
|---|---|---|
Market Cap | $9.43B | $10.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $356.25 | $133.34 |
52-Week Low | $241.71 | $94.37 |
Enterprise Value | $9.18B | $21.03B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $357.58, up 0.86% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported a Q2 2026 earnings beat with EPS of $2.62 versus $1.75 expected, and net income for 2025 reached $759.9 million, a significant recovery from prior years. Analyst sentiment is positive with a consensus buy rating and a $350 price target, though the P/E ratio of 43.39 suggests a premium valuation.
The outlook for BIO is cautiously optimistic, driven by earnings momentum and improving cash flow, but risks include high valuation, competitive pressures in life sciences, and reliance on academic research markets. Upside potential exists if international revenue trends strengthen, but investors should monitor margin sustainability and debt levels, which have improved but remain a focus.
Wynn Resorts (WYNN) trades at $104.59, up 2.04% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations, driven by Macau performance, though U.S. margins face pressure. The company maintains solid revenue growth but carries high debt levels, with net cash flow negative due to significant capital expenditures for expansion projects like Wynn Al Marjan.
The outlook is cautiously optimistic, with a consensus price target of $133 offering ~27% upside. Key opportunities include Macau recovery and new project growth, while risks involve high leverage, rising capex, and regional economic sensitivity. Investors should weigh strong institutional support against execution risks in upcoming expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
